Shattuck Labs Inc
STTK3.770USD
+0.200+5.60%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
238.08MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Shattuck Labs Inc Unternehmen
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
Shattuck Labs Inc Informationen
BörsenkürzelSTTK
Name des UnternehmensShattuck Labs Inc
IPO-datumOct 09, 2020
CEOSchreiber (Taylor)
Anzahl der mitarbeiter44
WertpapierartOrdinary Share
GeschäftsjahresendeOct 09
Addresse500 W. 5Th Street
StadtAUSTIN
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl78701
Telefon15129004690
Websitehttps://www.shattucklabs.com/
BörsenkürzelSTTK
IPO-datumOct 09, 2020
CEOSchreiber (Taylor)
Führungskräfte von Shattuck Labs Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Taylor Schreiber, M.D., Ph.D.
Dr. Taylor Schreiber, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
96.61K
+25610.00%
Dr. Stephen Stout, Ph.D.
Dr. Stephen Stout, Ph.D.
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
81.53K
-4746.00%
Dr. George S. Golumbeski, Ph.D.
Dr. George S. Golumbeski, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.61K
--
Dr. Neil W. Gibson ,Ph.D.
Dr. Neil W. Gibson ,Ph.D.
Independent Director
Independent Director
52.74K
--
Dr. Arundathy Nirmalini (Lini) Pandite
Dr. Arundathy Nirmalini (Lini) Pandite
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Casi Deyoung
Ms. Casi Deyoung
Chief Business Officer
Chief Business Officer
--
--
Mr. Andrew R. Neill
Mr. Andrew R. Neill
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
Mr. Conor Richardson, CPA
Mr. Conor Richardson, CPA
Senior Director, Finance & Investor Relations
Senior Director, Finance & Investor Relations
--
--
Dr. Abhinav A. Shukla, Ph.D.
Dr. Abhinav A. Shukla, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Taylor Schreiber, M.D., Ph.D.
Dr. Taylor Schreiber, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
96.61K
+25610.00%
Dr. Stephen Stout, Ph.D.
Dr. Stephen Stout, Ph.D.
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
81.53K
-4746.00%
Dr. George S. Golumbeski, Ph.D.
Dr. George S. Golumbeski, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.61K
--
Dr. Neil W. Gibson ,Ph.D.
Dr. Neil W. Gibson ,Ph.D.
Independent Director
Independent Director
52.74K
--
Dr. Arundathy Nirmalini (Lini) Pandite
Dr. Arundathy Nirmalini (Lini) Pandite
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Casi Deyoung
Ms. Casi Deyoung
Chief Business Officer
Chief Business Officer
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Fri, Jan 30
Aktualisiert: Fri, Jan 30
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
T. Rowe Price Investment Management, Inc.
11.65%
OrbiMed Advisors, LLC
9.97%
Adage Capital Management, L.P.
9.97%
Redmile Group, LLC
8.75%
Prosight Capital
8.61%
Andere
51.05%
Aktionäre
Aktionäre
Anteil
T. Rowe Price Investment Management, Inc.
11.65%
OrbiMed Advisors, LLC
9.97%
Adage Capital Management, L.P.
9.97%
Redmile Group, LLC
8.75%
Prosight Capital
8.61%
Andere
51.05%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
23.34%
Investment Advisor
17.02%
Investment Advisor/Hedge Fund
14.68%
Private Equity
9.97%
Corporation
9.51%
Family Office
2.58%
Research Firm
2.11%
Individual Investor
1.80%
Venture Capital
0.04%
Andere
18.95%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
186
35.95M
56.82%
+4.07M
2025Q3
179
32.72M
51.71%
-1.24M
2025Q2
186
35.33M
73.76%
-6.35M
2025Q1
190
36.10M
75.45%
-5.76M
2024Q4
182
37.00M
77.49%
-7.77M
2024Q3
191
41.87M
87.75%
-1.86M
2024Q2
194
39.66M
83.35%
+16.66K
2024Q1
209
37.10M
79.60%
-1.39M
2023Q4
203
34.54M
71.04%
+5.75M
2023Q3
205
27.35M
64.28%
-7.93M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
OrbiMed Advisors, LLC
6.31M
9.97%
+6.31M
--
Sep 30, 2025
Adage Capital Management, L.P.
6.31M
9.97%
+1.63M
+34.89%
Sep 30, 2025
Redmile Group, LLC
5.54M
8.75%
--
--
Sep 30, 2025
Prosight Capital
5.45M
8.61%
-1.19M
-17.89%
Sep 30, 2025
Hornblower Capital Holdings, LLC
2.89M
4.57%
--
--
Apr 01, 2025
Houghton Capital Holdings, LLC
2.61M
4.13%
--
--
Apr 01, 2025
The Vanguard Group, Inc.
2.13M
3.36%
-19.77K
-0.92%
Sep 30, 2025
683 Capital Management LLC
1.53M
2.42%
+437.22K
+39.93%
Sep 30, 2025
The Clark Estates Inc.
1.48M
2.33%
--
--
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Texas Capital Texas Equity Index ETF
0%
iShares Russell 2000 Value ETF
0%
ProShares UltraPro Russell2000
0%
Dimensional US Core Equity 1 ETF
0%
ProShares Hedge Replication ETF
0%
iShares Morningstar Small-Cap ETF
0%
iShares Russell 2000 ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
Texas Capital Texas Small Cap Equity Index ETF
0%
Mehr Anzeigen
Texas Capital Texas Equity Index ETF
Anteil0%
iShares Russell 2000 Value ETF
Anteil0%
ProShares UltraPro Russell2000
Anteil0%
Dimensional US Core Equity 1 ETF
Anteil0%
ProShares Hedge Replication ETF
Anteil0%
iShares Morningstar Small-Cap ETF
Anteil0%
iShares Russell 2000 ETF
Anteil0%
Avantis US Small Cap Equity ETF
Anteil0%
iShares Micro-Cap ETF
Anteil0%
Texas Capital Texas Small Cap Equity Index ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
